Monte Rosa Therapeutics presented data at the American Association for Cancer Research (AACR) Annual Meeting showing that its cyclin E1‑directed molecular‑glue degrader, MRT‑55811, produced deep tumor regressions in CCNE1‑amplified in‑vivo models of ovarian, breast, and gastric cancers. The data demonstrate superior selectivity compared with clinical‑stage CDK2 inhibitors, suggesting that the degrader could avoid the dose‑limiting toxicities associated with less selective agents.
"MRT‑55811 also exhibited superior selectivity when compared to clinical‑stage CDK2 inhibitors, suggesting that our CCNE1‑directed MGDs could avoid the dose‑limiting toxicities reported for these less selective agents," said Sharon Townson, Chief Scientific Officer of Monte Rosa Therapeutics.
"CCNE1 MGDs represent a first‑in‑class opportunity to directly target a frequently amplified driver oncogene in several solid tumor cancer populations with high unmet medical need. In CCNE1‑amplified in vivo models of ovarian, gastric, and breast cancer, MRT‑55811 demonstrated compelling monotherapy anti‑tumor activity," added Townson.
The company’s QuEEN discovery engine was credited with identifying cyclin E1 as a previously undruggable target, and Monte Rosa plans to file an Investigational New Drug application for the program later in 2026, marking a critical step toward clinical development.
Analysts have revised earnings estimates upward following the announcement, reflecting confidence in the program’s potential to advance the company’s pipeline and strengthen its position as a leader in molecular‑glue degrader technology.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.